Circulating Tumor Cells in Uveal Melanoma: Multi-Marker Detection and Association With Disease State
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.1.55 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Daniel P de Bruyn and 14 co-authors. Institution: Department of Ophthalmology, Erasmus MC, The Netherlands. Major MEDLINE topics: Uveal Neoplasms, Neoplastic Cells, Circulating, Melanoma, Biomarkers, Tumor. 56 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Purpose
Uveal melanoma (UM) is primarily treated with eye-sparing radiotherapy, leaving limited tumor tissue for molecular analysis. Circulating tumor cells (CTCs) may offer a minimally invasive alternative for genomic tumor profiling. This pilot study evaluated the feasibility of a multi-marker CTC capture approach in UM patients at diagnosis, during fractionated stereotactic radiotherapy (fSRT), and at metastatic progression.
Methods
Patients with localized or metastatic UM were prospectively enrolled. Peripheral blood samples were collected at baseline, during fSRT, and on detection of metastases. CTCs were captured and enumerated using a multi-marker approach and fluorescence microscopy.
Results
A total of 76 patients were included: 68 with localized disease and eight with metastatic disease. Four patients presented initially with localized disease but developed metastasis during follow-up: for comparisons, only metastatic-stage samples were used, yielding 64 localized and 12 metastatic samples. CTCs were detected in 69.1% of patients with localized disease at baseline and in 83.3% of those with metastases. CTC counts were significantly higher in metastatic disease than in localized disease (median = 8 vs. 3; P = 0.010). Among patients undergoing fSRT, paired analysis showed a significant increase in CTC counts between day 3 and day 5 (median = 1 vs. 4; P = 0.007). No significant associations were observed between baseline CTC counts and tumor thickness, largest basal diameter, tumor volume, American Joint Committee on Cancer tumor stage, tumor location, or molecular risk class.
Conclusions
Multi-marker CTC detection in UM patients is feasible across disease stages. Increased CTC counts during fSRT may offer a window for molecular characterization. Larger studies with longitudinal blood sampling are needed to validate clinical and prognostic utility.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Erasmus MC, The Netherlands.
- Department of Clinical Genetics, Erasmus MC, The Netherlands.
- Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia.
- Department of Clinical Oncology, Erasmus MC, The Netherlands.
- Department of Pathology, Section Ophthalmic Pathology, Erasmus MC, The Netherlands.
- Department of Ophthalmic Pathology, Leiden University Medical Centre, Leiden, The Netherlands.
Cite
APA
de Bruyn, D. P., Bassil, F. L., Wu, M., Beasley, A. B., Vaarwater, J., Van, M. N., Kraan, J., Verdijk, R. M., Paridaens, D., van Rij, C. M., Naus, N. C., de Klein, A., Gray, E. S., Brosens, E., & Kiliç, E. (2026). Circulating Tumor Cells in Uveal Melanoma: Multi-Marker Detection and Association With Disease State. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.1.55
Vancouver
de Bruyn DP, Bassil FL, Wu M, Beasley AB, Vaarwater J, Van MN, et al. Circulating Tumor Cells in Uveal Melanoma: Multi-Marker Detection and Association With Disease State. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.1.55
BibTeX
@article{deBruyn2026,
author = {de Bruyn, Daniel P and Bassil, Fabiana Lucia and Wu, Mike and Beasley, Aaron B and Vaarwater, Jolanda and Van, Mai N and Kraan, Jaco and Verdijk, Robert M and Paridaens, Dion and van Rij, Caroline M and Naus, Nicole C and de Klein, Annelies and Gray, Elin S and Brosens, Erwin and Kiliç, Emine},
title = {Circulating Tumor Cells in Uveal Melanoma: Multi-Marker Detection and Association With Disease State},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.1.55}
}
EUVIMED